Thursday, June 25, 2015 10:49:51 AM
The question is, are they eligible for the NASDAQ?
Take away the recent settlement that went into last Q's revenues and their financials don't look so hot. But I didn't look any further into it than that, so.....
ITUS Announces Reverse Stock Split With the Intention to List Shares on NASDAQ
LOS ANGELES, CA--(Marketwired - June 25, 2015) - ITUS Corporation ("ITUS") (OTCQB: ITUS), today announced that effective at 9:00 a.m. Eastern Standard Time on Friday, June 26, 2015, the company will implement a 1 for 25 reverse stock split of its common shares. The company's common stock will begin trading on a post-reverse stock split basis on the OTCQB under the temporary symbol "ITUSD" effective with the open of business on June 26, 2015. The company's shareholders approved implementation of a reverse stock split on August 8, 2014, and the company's board of directors has determined to take such action to help the company become eligible for listing on The NASDAQ Stock Market.
Robert Berman, ITUS's President and CEO, stated, "The excessively large number of outstanding ITUS shares has been an ongoing concern raised by investors and others in the financial community. With the announcement of our new business direction and the launch of exciting initiatives such as Anixa, our cancer diagnostics subsidiary, the timing is right to clean up the capital structure of the company as we complete our transformation and position the company for long term success."
As a result of the reverse stock split, every 25 shares of ITUS's issued and outstanding shares of common stock will be automatically converted into 1 share of common stock. Any fractional shares resulting from the reverse stock split will be rounded up to the nearest whole share. Additionally, as a result of the reverse stock split the number of shares of ITUS's common stock and preferred stock authorized under our Certificate of Incorporation, as amended, will be decreased by the same proportion as the outstanding shares of common stock.
The reverse stock split will reduce the number of ITUS's issued and outstanding common stock from approximately 219 million shares, pre-reverse stock split, to approximately 8.8 million shares, post-reverse stock split. In most instances, the only way to obtain new ITUS share certificates will be to physically exchange old share certificates. To facilitate a smooth transition, we recommend that shareholders first obtain possession of their physical stock certificates. If necessary, shareholders should request such certificates from their brokers, if they have not already done so. Shareholders will receive detailed instructions for obtaining new share certificates from the company's transfer agent within the next 6 weeks, and instructions will also be made available in the "Investor" section of the ITUS website. A new CUSIP number of 45069V203 will replace the pre-reverse split CUSIP number of 45069V104 to distinguish between the company's pre- and post-reverse split shares of common stock.
You can lead a horse to water. But you can't make him get down on one knee and do an Al Jolson impression!
Recent ANIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 12:35:37 PM
- Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines • PR Newswire (US) • 05/08/2024 12:25:00 PM
- Anixa Biosciences CEO Featured on "Target: Cancer Podcast" by Oncologist Dr. Sanjay Juneja • PR Newswire (US) • 05/06/2024 12:05:00 PM
- Anixa Biosciences to Participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024 • PR Newswire (US) • 04/30/2024 11:45:00 AM
- Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board • PR Newswire (US) • 04/18/2024 12:20:00 PM
- Anixa Biosciences 2024 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties • PR Newswire (US) • 03/14/2024 12:45:00 PM
- Anixa Biosciences Announces Presentation at 24th Annual World Vaccine Congress • PR Newswire (US) • 03/11/2024 12:00:00 PM
- Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical Trial • PR Newswire (US) • 02/12/2024 12:30:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/08/2024 09:15:32 PM
- Anixa Biosciences Announces Participation in 2024 NeauxCancer Oncology Conference • PR Newswire (US) • 01/29/2024 01:50:00 PM
- Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology • PR Newswire (US) • 01/23/2024 12:55:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 12:08:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 12:07:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 12:07:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 12:05:55 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 12:05:16 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/16/2024 10:29:43 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/16/2024 09:43:17 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 01/16/2024 09:30:49 PM
- Anixa Biosciences to Present at Sidoti Micro-Cap Virtual Conference on January 17, 2024 • PR Newswire (US) • 01/10/2024 02:00:00 PM
- Anixa Biosciences to Present at Biotech Showcase 2024 • PR Newswire (US) • 12/14/2023 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 11:01:47 AM
- Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine • PR Newswire (US) • 12/06/2023 11:00:00 PM
- Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine • PR Newswire (US) • 12/06/2023 09:05:00 PM
- Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology • PR Newswire (US) • 11/27/2023 01:30:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM